Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Emergency Service, Hospital, Social Determinants of Health
Interventions: Health-related social needs decision support system; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 518,512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Food-effect
Interventions: Ecopipam tablet; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyps
Interventions: EndoVigilant CAD Software; Device
Lead sponsor: EndoVigilant Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Palo Alto, California • Greenbelt, Maryland

Conditions: Cardiovascular Health Risk Communication, Cardiovascular (CV) Risk, Cardiovascular Disease Prevention
Interventions: Cardiac CT Scan, Bloodwork; Diagnostic Test
Lead sponsor: Northwell Health; Other
Eligibility: 55 Years to 65 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions: Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test; Procedure · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 9,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 91
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Searcy, Arkansas + 79 more

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Brain Concussion, Mild Cognitive Impairment
Interventions: Pen and paper neuropsychological test, Quick Test; Other · Device
Lead sponsor: ImPACT Applications, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Crofton, Maryland + 1 more

Conditions: Psoriasis, Obesity
Interventions: Adipose tissue biopsy (fat biopsy); Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Blood Pressure, Neurovascular Control
Interventions: Time-Restricted Feeding; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Clinical Trial
Interventions: SMS/Text (CAMPI), Fidelity Monitoring (Lyssn and COACH), Family Check-Up 4 Health (FCU4Health); Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 2 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteer
Interventions: BIIB142, BIIB142-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Multiple Sclerosis
Interventions: F-18 3F4AP; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Covid19
Interventions: COVID-19 antigen and antibody tests, and influenza rapid test; Diagnostic Test
Lead sponsor: Polk County Fire Rescue; Government
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bartow, Florida

Conditions: Healthy Volunteers
Interventions: GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Pregnancy, Labor Pain
Interventions: Routine oxytocin, Half-dose oxytocin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer Study
Interventions: Glasdegib Oral Tablet, Glasdegib IV infusion; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type2 Diabetes
Interventions: Afrezza Inhalant Product; Drug
Lead sponsor: Model Clinical Research LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: High Intensity Interval Gait training, Moderate Intensity Interval gait training; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Improving Cardiometabolic Outcomes in Older Adults
Interventions: Melatonin 1 mg, Placebos, Meal timing, Non-Meal timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis, Sickle Cell Disease, SARS CoV 2 Infection
Interventions: Exercise; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Irvine, California

Search by objective public record fields.

Predictive Modeling for Social Needs in Emergency Department Settings

Food-effect Study of Ecopipam Pharmacokinetics

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Computer Aided Detection of Polyps During Colonoscopy Procedures

Breast Artery Calcification (BAC) and Female Cardiovascular Disease

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Development of a Neurocognitive Screening Test

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Meal Timing and Blood Pressure

Primary Care Evidence-based Approach for Improving Lifelong Health

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Polk COVID-19 and Flu Response

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

Glasdegib Absolute Bioavailability Study

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

High Intensity Interval Gait Training in Multiple Sclerosis

Aging Program Project Grant 6

Exercise in Child Health